More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
GlobalData on MSN18h
FDA approves Gomekli as first neurofibromatosis drug for adultsFailed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.
The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...
The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback